Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

This study found that growth factor concentrate injections combined with topical minoxidil in androgenetic alopecia patients led to similar hair regrowth outcomes as platelet-rich plasma, with lower reported pain.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This randomized clinical trial observed that Facia Men’s capsule significantly reduced hair shedding in men with androgenetic alopecia over 12 weeks without affecting renal or liver function, though a small change in blood glucose suggests monitoring metabolic health.

This study found that Facia Men’s capsule significantly reduced hair shedding in men with androgenetic alopecia over 12 weeks, without notable renal or liver safety concerns.

This study found that Asthimajjapachak Churna provided significantly more therapeutic relief from hair fall than Shwadamshtradi Rasayana Churna in young females over 30 days.

The study found that Asthimajjapachak Churna led to greater improvement in managing hair fall among young females compared to Shwadamshtradi Rasayana Churna, particularly through alleviation of Asthigata dosha.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This randomized trial found that diode laser achieved more favorable long-term hair removal outcomes but induced more discomfort and transient adverse effects compared to intense pulsed light in women with Fitzpatrick skin types I-IV.

This randomized clinical trial found that adjunctive apple cider vinegar supplementation significantly improved the resolution of metabolic syndrome, reduced insulin resistance, and enhanced quality of life and sexual function in women with PCOS and metabolic syndrome, compared to a placebo group.

This study found that salmon tissue-derived exosomes showed significantly greater improvements in hair density and other parameters compared to platelet-rich plasma in patients with mild to moderate androgenetic alopecia.

This clinical trial found that using a 45-degree angled implanter with the bevel facing the skin in FUE hair transplantation significantly reduced insertion resistance, graft popping, and bleeding, while improving efficiency and graft alignment compared to conventional methods.

In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.

This source reports that in adults with non-scarring alopecia, polyphenolic interventions significantly improved hair density and total area hair count compared to controls, although considerable variability was present in results, highlighting the need for further research.

This systematic review and meta-analysis found that polyphenolic interventions significantly improved hair density and total area hair count in adults with non-scarring alopecia, but substantial heterogeneity was observed.

This study evaluated the efficacy of polyphenolic compounds for hair growth in adults with non-scarring alopecia and found that these interventions significantly improved hair density and total area hair count compared to controls, although results were not significantly different from minoxidil.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

Keratinocyte Growth Factor-Hair Serum may help prevent hair loss during chemotherapy, but more research is needed.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

This upcoming clinical trial at Shenzhen People's Hospital will explore the safety and efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles as a treatment for androgenetic alopecia in young men, comparing them to minoxidil. Results are not reported yet.

In this study, oral Bhringaraj extract was found to significantly reduce hair shedding in adults over 24 weeks, according to comb test measurements and patient-reported improvements, with mild and self-resolving side effects observed.

This study found that treatment with human foreskin fibroblast conditioned medium improved both objective measures like hair density and subjective satisfaction in patients with androgenetic alopecia.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia compared to minoxidil alone, despite mild adverse events, and microneedling parameters like depth and duration did not significantly affect outcomes.

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.